search
Back to results

Luteal Phase FSH in the IVF Poor Responder

Primary Purpose

Infertility

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
follitropin beta
ganirelix acetate
Sponsored by
University of Pennsylvania
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infertility focused on measuring infertility, in vitro fertilization

Eligibility Criteria

20 Years - 42 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Infertile women planning to undergo IVF Poor ovarian response in most-recent previous IVF cycle within the past 18 months as defined by the following criteria: A) <5 dominant follicles day of hCG, B) <5 oocytes retrieved, or C) cancellation of a previous IVF cycle due to poor response to ovulation stimulation. Aged 20-42 (inclusive) at the time of randomization Presence of both ovaries Normal pap smear within past three years At least 45 days after the last IVF cycle Be willing and able to comply with the protocol for the duration of the study Have given written informed consent, prior to any study-related procedure, not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care. Exclusion Criteria: Clinically significant systemic disease Current regular cigarette smoking by patient report Known to be positive for Human Immunodeficiency Virus Any medical condition which, in the judgment of the investigator and sponsor, may interfere with the absorption, distribution, metabolism or excretion of the medications used Abnormal, undiagnosed gynecological bleeding Known allergy or hypersensitivity to human gonadotropin preparations Simultaneous participation in another investigational drug or device trial Subject fails, in 2 separate menstrual cycle attempts, to have FSH ≤12.0 and an ultrasound exam within normal limits (per standard for IVF) at the Baseline Visit For subjects randomized to the Luteal Phase Regimen, failure to ovulate in 2 separate menstrual cycle attempts, as evidenced by ovulation predictor kit, progesterone level, and /or visualization of corpus luteum cyst on an ovary by ultrasound exam at the Luteal Visit

Sites / Locations

  • University of Pennsylvania Reproductive Research Unit

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

1

2

Arm Description

Follitropin beta

Ganirelix acetate

Outcomes

Primary Outcome Measures

Number of oocytes retrieved for IVF

Secondary Outcome Measures

Number of follicles >10mm on day of human chorionic gonadotropin (hCG) administration;
Number of days of stimulation;
Estradiol level on the day of hCG administration;
Clinical pregnancy rate per transfer: defined as the presence of an intrauterine sac on transvaginal ultrasound;
Delivery rate per transfer;
Safety (incidence of ovarian torsion, severe risk of ovarian hyperstimulation syndrome, enlarging hemorrhagic cysts, and serious adverse events)

Full Information

First Posted
September 21, 2005
Last Updated
December 1, 2015
Sponsor
University of Pennsylvania
search

1. Study Identification

Unique Protocol Identification Number
NCT00225433
Brief Title
Luteal Phase FSH in the IVF Poor Responder
Official Title
Luteal Phase Recombinant FSH vs. Follicular Phase Recombinant FSH for IVF Stimulation in the Poor Responder
Study Type
Interventional

2. Study Status

Record Verification Date
December 2015
Overall Recruitment Status
Completed
Study Start Date
September 2005 (undefined)
Primary Completion Date
December 2006 (Actual)
Study Completion Date
June 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Pennsylvania

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
In vitro fertilization (IVF) is a common procedure used to assist couples who have difficulty conceiving a pregnancy. IVF is a process where oocytes (eggs) are retrieved from a woman's ovaries and fertilized with sperm in the laboratory. In order to maximize the number of oocytes that can be retrieved, a women undergoes ovarian stimulation with recombinant follicle stimulating hormone (FSH). Typically 6-20 oocytes are retrieved, but in some cases there is a limited response to the stimulation, producing a limited number of oocytes. This is called poor ovarian response. This study is designed to objectively compare two treatment regimens currently advocated in clinical practice, but never compared directly. The purpose is to assess ovarian response to starting treatment at the end of the preceding cycle may increase the number of developing oocytes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility
Keywords
infertility, in vitro fertilization

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
Follitropin beta
Arm Title
2
Arm Type
Active Comparator
Arm Description
Ganirelix acetate
Intervention Type
Drug
Intervention Name(s)
follitropin beta
Intervention Description
Follitropin beta
Intervention Type
Drug
Intervention Name(s)
ganirelix acetate
Intervention Description
Ganirelix acetate
Primary Outcome Measure Information:
Title
Number of oocytes retrieved for IVF
Time Frame
One cycle
Secondary Outcome Measure Information:
Title
Number of follicles >10mm on day of human chorionic gonadotropin (hCG) administration;
Time Frame
1 cycle
Title
Number of days of stimulation;
Time Frame
1 cycle
Title
Estradiol level on the day of hCG administration;
Time Frame
1 cycle
Title
Clinical pregnancy rate per transfer: defined as the presence of an intrauterine sac on transvaginal ultrasound;
Time Frame
1 cycle
Title
Delivery rate per transfer;
Time Frame
1 cycle
Title
Safety (incidence of ovarian torsion, severe risk of ovarian hyperstimulation syndrome, enlarging hemorrhagic cysts, and serious adverse events)
Time Frame
1 cycle

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
42 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Infertile women planning to undergo IVF Poor ovarian response in most-recent previous IVF cycle within the past 18 months as defined by the following criteria: A) <5 dominant follicles day of hCG, B) <5 oocytes retrieved, or C) cancellation of a previous IVF cycle due to poor response to ovulation stimulation. Aged 20-42 (inclusive) at the time of randomization Presence of both ovaries Normal pap smear within past three years At least 45 days after the last IVF cycle Be willing and able to comply with the protocol for the duration of the study Have given written informed consent, prior to any study-related procedure, not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care. Exclusion Criteria: Clinically significant systemic disease Current regular cigarette smoking by patient report Known to be positive for Human Immunodeficiency Virus Any medical condition which, in the judgment of the investigator and sponsor, may interfere with the absorption, distribution, metabolism or excretion of the medications used Abnormal, undiagnosed gynecological bleeding Known allergy or hypersensitivity to human gonadotropin preparations Simultaneous participation in another investigational drug or device trial Subject fails, in 2 separate menstrual cycle attempts, to have FSH ≤12.0 and an ultrasound exam within normal limits (per standard for IVF) at the Baseline Visit For subjects randomized to the Luteal Phase Regimen, failure to ovulate in 2 separate menstrual cycle attempts, as evidenced by ovulation predictor kit, progesterone level, and /or visualization of corpus luteum cyst on an ovary by ultrasound exam at the Luteal Visit
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kurt T Barnhart, MD, MSCE
Organizational Affiliation
University of Pennsylvania
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Pennsylvania Reproductive Research Unit
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Luteal Phase FSH in the IVF Poor Responder

We'll reach out to this number within 24 hrs